AP NEWS

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MKL, MAXR, ATVI and TYME

February 4, 2019

CEDARHURST, N. Y. , Feb. 04, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Markel Corporation (NYSE: MKL)Investors Affected: July 26, 2017 - December 6, 2018

A class action has commenced on behalf of certain shareholders in Markel Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company’s subsidiaries did not appropriately record loss reserves; (2) as a result, the loss reserves would need to be adjusted and/or restated; (3) these misleading accounting practices would lead to regulatory scrutiny and financial loss to investors; and (4) as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kseclaw.com/securities/markel-corporation/?wire=3

Maxar Technologies Inc. (NYSE: MAXR)Investors Affected: March 29, 2018 - January 7, 2019

A class action has commenced on behalf of certain shareholders in Maxar Technologies Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Maxar improperly inflated the value of its intangible assets, among other accounting improprieties; (ii) Maxar’s highly-valued WorldView-4 was equipped with CMGs that were faulty and/or ill-suited for their designed and intended purpose; and (iii) as a result, Maxar’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/maxar-technologies-inc/?wire=3

Activision Blizzard, Inc. (NASDAQ: ATVI)Investors Affected: August 2, 2018 - January 10, 2019

A class action has commenced on behalf of certain shareholders in Activision Blizzard, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) the termination of Activision Blizzard and Bungie’s partnership, giving Bungie full publishing rights and responsibilities for the Destiny franchise, was imminent; (ii) the termination of the two companies’ relationship would foreseeably have a significant negative impact on Activision Blizzard’s revenues; and (iii) as a result, Activision Blizzard’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/activision-blizzard-inc-loss-submission-form/?wire=3

Tyme Technologies, Inc. (NASDAQCM: TYME)Investors Affected: March 14, 2018 - January 18, 2019

A class action has commenced on behalf of certain shareholders in Tyme Technologies, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Tyme had not adequately designed the Phase II Study to present reliable results on the efficacy of SM-88 on pancreatic cancer; (ii) Tyme had failed to include an appropriate control group in its open-label Phase II clinical trial for SM-88; (iii) the omission of an appropriate control group distorted the reliability of data showing the efficacy of SM-88 in the Phase II Study; and (iv) as a result, Tyme’s public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/tyme-technologies-inc/?wire=3

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company’s stock.

CONTACT:Kuznicki Law PLLCDaniel Kuznicki, Esq.445 Central Avenue, Suite 334Cedarhurst, NY 11516Email: dk@kclasslaw.com Phone: (347) 696-1134Cell: (347) 690-0692Fax: (347) 348-0967

AP RADIO
Update hourly